www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

Recombinant SARS-Cov-2 (Omicron, B.1.1.529) Spike trimer protein, C-His (HEK293)

Catalog Number:	bs-43077P
Concentration:	＞0.5 mg/ml
AA Seq:	16-1213/1273
Predicted MW:	137
Detected MW:	150-180 kDa
Tags:	C-His
Activity:	Not tested
Endotoxin:	Not analyzed
Purity:	>90% as determined by SDS-PAGE
Purification:	AC
Form:	Lyophilized or Liquid
Storage:	PBS (pH7.4). Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:	The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

VALIDATION IMAGES

The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.



Measured by its binding ability in a functional ELISA. Immobilized human ACE2, His-Avi Tag (Cat: bs-46001P) at 2μg/mL (100 μL/Well) can bind SARS-CoV-2 Spike trimer Protein (His Tag) (Omicron/B.1.1.529) (Cat: bs-43077P), the EC50 is 1.5μg/mL.



Measured by its binding ability in a indirect ELISA. Immobilized SARS-CoV-2 Spike trimer Protein (His Tag) (Omicron/B.1.1.529) (Cat: bs-43077P) at 2μg/mL (100 μL/Well) can bind Anti-SARS-CoV-2 Spike Monoclonal antibody (Cat:bsm-41622M&bsm-41476M&bsm-41630M).